Development of new effective therapies for rare diseases
The 'Development of new effective therapies for rare diseases' program, under Horizon Europe, aims to address the urgent unmet medical needs in rare diseases by fostering the development of novel therapeutic interventions. It specifically targets groups of rare diseases with commonalities, moving beyond single-disease approaches. The program encourages multidisciplinary collaborations and the involvement of patient representatives to accelerate the translation of research into accessible treatments.
Who is Funded
This program supports a broad range of entities and collaborations across various geographical areas, all united by the common goal of advancing therapies for rare diseases. It aims to significantly reduce the burden of diseases globally and strengthen healthcare systems.
What is Funded
This program provides funding for a diverse range of research and innovation activities across critical health sectors, focusing on advancing therapeutic solutions from early development to market uptake.
Type and Scope of Funding
The financial support provided through this program is in the form of grants, with a significant maximum funding amount per project to foster impactful research and development.
Conditions and Requirements
Applicants and beneficiaries must adhere to a series of specific conditions and requirements throughout the application and project implementation phases, encompassing administrative, collaborative, and regulatory stipulations.
Application Procedure
The application process for this program is structured in two stages, involving detailed evaluation criteria and specific timelines for submission and notification.
Legal Basis
The program is firmly rooted in established European Union legal frameworks and policies, ensuring transparency and proper governance.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
8,000,000 €
Allocated Budget:
60,000,000 EUR
Award Channel:
Framework Programme Call
Region:
European Union Member States and Associated Countries. Legal entities established in the United States of America are also eligible for funding. Other non-EU/non-Associated countries may also be eligible as specified in the Horizon Europe Programme Guide.
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development
Beneficiaries:
Patients with rare diseases, Healthcare providers
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development, Market Introduction, Commercialization
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Managed By:
Unknown
Additional Partners:
Joint Research Centre (JRC)
Website: